Interaction of hydrocortisone and illness severity on head growth in cohort of ELBW infants.
Journal
Pediatric research
ISSN: 1530-0447
Titre abrégé: Pediatr Res
Pays: United States
ID NLM: 0100714
Informations de publication
Date de publication:
Dec 2023
Dec 2023
Historique:
received:
21
12
2022
accepted:
15
05
2023
revised:
06
05
2023
medline:
24
11
2023
pubmed:
21
6
2023
entrez:
20
6
2023
Statut:
ppublish
Résumé
Extremely low birth weight (ELBW) infants comprise a fragile population at risk for neurodevelopmental disabilities (NDD). Systemic steroids were previously associated with NDD, but more recent studies suggest hydrocortisone (HCT) may improve survival without increasing NDD. However, the effects of HCT on head growth adjusted for illness severity during NICU hospitalization are unknown. Thus, we hypothesize that HCT will protect head growth, accounting for illness severity using a modified neonatal Sequential Organ Failure Assessment (M-nSOFA) score. We conducted a retrospective study that included infants born at 23-29 weeks gestational age (GA) and < 1000 g. Our study included 73 infants, 41% of whom received HCT. We found negative correlations between growth parameters and age, similar between HCT and control patients. HCT-exposed infants had lower GA but similar normalized birth weights; HCT-exposed infants also had higher illness severity and longer lengths of hospital stay. We found an interaction between HCT exposure and illness severity on head growth, such that infants exposed to HCT had better head growth compared to those not exposed to HCT when adjusted for illness severity. These findings emphasize the importance of considering patient illness severity and suggest that HCT use may offer additional benefits not previously considered. This is the first study to assess the relationship between head growth and illness severity in extremely preterm infants with extremely low birth weights during their initial NICU hospitalization. Infants exposed to hydrocortisone (HCT) were overall more ill than those not exposed, yet HCT exposed infants had better preserved head growth relative to illness severity. Better understanding of the effects of HCT exposure on this vulnerable population will help guide more informed decisions on the relative risks and benefits for HCT use.
Sections du résumé
BACKGROUND
BACKGROUND
Extremely low birth weight (ELBW) infants comprise a fragile population at risk for neurodevelopmental disabilities (NDD). Systemic steroids were previously associated with NDD, but more recent studies suggest hydrocortisone (HCT) may improve survival without increasing NDD. However, the effects of HCT on head growth adjusted for illness severity during NICU hospitalization are unknown. Thus, we hypothesize that HCT will protect head growth, accounting for illness severity using a modified neonatal Sequential Organ Failure Assessment (M-nSOFA) score.
METHODS
METHODS
We conducted a retrospective study that included infants born at 23-29 weeks gestational age (GA) and < 1000 g. Our study included 73 infants, 41% of whom received HCT.
RESULTS
RESULTS
We found negative correlations between growth parameters and age, similar between HCT and control patients. HCT-exposed infants had lower GA but similar normalized birth weights; HCT-exposed infants also had higher illness severity and longer lengths of hospital stay. We found an interaction between HCT exposure and illness severity on head growth, such that infants exposed to HCT had better head growth compared to those not exposed to HCT when adjusted for illness severity.
CONCLUSION
CONCLUSIONS
These findings emphasize the importance of considering patient illness severity and suggest that HCT use may offer additional benefits not previously considered.
IMPACT
CONCLUSIONS
This is the first study to assess the relationship between head growth and illness severity in extremely preterm infants with extremely low birth weights during their initial NICU hospitalization. Infants exposed to hydrocortisone (HCT) were overall more ill than those not exposed, yet HCT exposed infants had better preserved head growth relative to illness severity. Better understanding of the effects of HCT exposure on this vulnerable population will help guide more informed decisions on the relative risks and benefits for HCT use.
Identifiants
pubmed: 37340101
doi: 10.1038/s41390-023-02689-w
pii: 10.1038/s41390-023-02689-w
doi:
Substances chimiques
Hydrocortisone
WI4X0X7BPJ
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1958-1965Informations de copyright
© 2023. The Author(s), under exclusive licence to the International Pediatric Research Foundation, Inc.
Références
Volpe, J. J. Brain injury in premature infants: A complex amalgam of destructive and developmental disturbances. Lancet Neurol. 8, 15 (2009).
doi: 10.1016/S1474-4422(08)70294-1
Montagna, A. & Nosarti, C. Socio-emotional development following very preterm birth: Pathways to psychopathology. Front. Psychol. 7, 80 (2016).
doi: 10.3389/fpsyg.2016.00080
pubmed: 26903895
pmcid: 4751757
Delobel-Ayoub, M. et al. Behavioral problems and cognitive performance at 5 years of age after very preterm birth: The EPIPAGE study. PEDIATRICS 123, 1485–1492 (2009).
doi: 10.1542/peds.2008-1216
pubmed: 19482758
Joseph, R. M. et al. Neurocognitive and Academic outcomes at age 10 years of extremely preterm newborns. Pediatrics 137, e20154343 (2016).
doi: 10.1542/peds.2015-4343
pubmed: 27006473
pmcid: 4811321
Thompson, D. K. et al. Tracking regional brain growth up to age 13 in children born term and very preterm. Nat. Commun. 11, 696 (2020).
doi: 10.1038/s41467-020-14334-9
pubmed: 32019924
pmcid: 7000691
Keunen, K. et al. Brain tissue volumes in preterm infants: prematurity, perinatal risk factors and neurodevelopmental outcome: A systematic review. J. Matern. Fetal Neonatal Med. 25, 89–100 (2012).
doi: 10.3109/14767058.2012.664343
pubmed: 22348253
Yates, N., Gunn, A. J., Bennet, L., Dhillon, S. K. & Davidson, J. O. Preventing brain injury in the preterm infant—current controversies and potential therapies. Int. J. Mol. Sci. 22, 1671 (2021).
doi: 10.3390/ijms22041671
pubmed: 33562339
pmcid: 7915709
Ibrahim, H., Sinha, I. P. & Subhedar, N. V. Corticosteroids for treating hypotension in preterm infants. Cochrane Database Syst. Rev. 2011, CD003662 (2011).
pubmed: 22161379
pmcid: 7133776
Doyle, L. W., Ehrenkranz, R. A. & Halliday, H. L. Late (> 7 days) postnatal corticosteroids for chronic lung disease in preterm infants. Cochrane Database Syst. Rev. https://doi.org/10.1002/14651858.CD001145.pub3 . (2014).
Halliday, H. L. Update on postnatal steroids. Neonatology 111, 415–422 (2017).
doi: 10.1159/000458460
pubmed: 28538237
Barrington, K. J. The adverse neuro-developmental effects of postnatal steroids in the preterm infant: a systematic review of RCTs. BMC Pediatr. 1, 1 (2001).
doi: 10.1186/1471-2431-1-1
pubmed: 11248841
pmcid: 29104
Yeh, T. F. et al. Outcomes at School Age after Postnatal Dexamethasone Therapy for Lung Disease of Prematurity. N. Engl. J. Med. 350, 1304–1313 (2004).
doi: 10.1056/NEJMoa032089
pubmed: 15044641
Parikh, N. A. et al. Postnatal dexamethasone therapy and cerebral tissue volumes in extremely low birth weight infants. Pediatrics 119, 265–272 (2007).
doi: 10.1542/peds.2006-1354
pubmed: 17272615
Cummings, J. J., Pramanik, A. K., & COMMITTEE ON FETUS AND NEWBORN. Postnatal Corticosteroids to Prevent or Treat Chronic Lung Disease Following Preterm Birth. Pediatrics e2022057530. https://doi.org/10.1542/peds.2022-057530 . (2022).
Baud, O. et al. Effect of early low-dose hydrocortisone on survival without bronchopulmonary dysplasia in extremely preterm infants (PREMILOC): A double-blind, placebo-controlled, multicentre, randomised trial. Lancet 387, 1827–1836 (2016).
doi: 10.1016/S0140-6736(16)00202-6
pubmed: 26916176
Onland, W. et al. Effect of hydrocortisone therapy initiated 7 to 14 days after birth on mortality or bronchopulmonary dysplasia among very preterm infants receiving mechanical ventilation: A randomized clinical trial. JAMA 321, 354 (2019).
doi: 10.1001/jama.2018.21443
pubmed: 30694322
pmcid: 6439762
Watterberg, K. L. et al. Hydrocortisone to improve survival without bronchopulmonary dysplasia. N. Engl. J. Med. 386, 1121–1131 (2022).
doi: 10.1056/NEJMoa2114897
pubmed: 35320643
pmcid: 9107291
Parikh, N. A., Kennedy, K. A., Lasky, R. E., McDavid, G. E. & Tyson, J. E. Pilot randomized trial of hydrocortisone in ventilator-dependent extremely preterm infants: effects on regional brain volumes. J. Pediatr. 162, 685–690.e1 (2013).
doi: 10.1016/j.jpeds.2012.09.054
pubmed: 23140612
Aziz, K. B. et al. Maximum vasoactive-inotropic score and mortality in extremely premature, extremely low birth weight infants. J. Perinatol. https://doi.org/10.1038/s41372-021-01030-9 (2021).
Lavilla, O. C. et al. Hourly kinetics of critical organ dysfunction in extremely preterm infants. Am. J. Respir. Crit. Care Med. 205, 75–87 (2022).
doi: 10.1164/rccm.202106-1359OC
pubmed: 34550843
Cheong, J. L. Y. et al. Head growth in preterm infants: correlation with magnetic resonance imaging and neurodevelopmental outcome. PEDIATRICS 121, e1534–e1540 (2008).
doi: 10.1542/peds.2007-2671
pubmed: 18519457
Raghuram, K. et al. Head growth trajectory and neurodevelopmental outcomes in preterm neonates. Pediatrics 140, e20170216 (2017).
doi: 10.1542/peds.2017-0216
pubmed: 28759409
Fenton, T. R. & Kim, J. H. A systematic review and meta-analysis to revise the Fenton growth chart for preterm infants. BMC Pediatr. 13, 59 (2013).
doi: 10.1186/1471-2431-13-59
pubmed: 23601190
pmcid: 3637477
Parry, G., Tucker, J. & Tarnow-Mordi, W. CRIB II: an update of the clinical risk index for babies score. Lancet 361, 1789–1791 (2003).
doi: 10.1016/S0140-6736(03)13397-1
pubmed: 12781540
Aziz, K. B., Schles, E. M., Makker, K. & Wynn, J. L. Frequency of acute kidney injury and association with mortality among extremely preterm infants. JAMA Netw. Open 5, e2246327 (2022).
doi: 10.1001/jamanetworkopen.2022.46327
pubmed: 36512358
pmcid: 9856227
Fleiss, N. et al. Evaluation of the neonatal sequential organ failure assessment and mortality risk in preterm infants with late-onset infection. JAMA Netw. Open 4, e2036518 (2021).
doi: 10.1001/jamanetworkopen.2020.36518
pubmed: 33538825
pmcid: 7862993
Wynn, J. L. & Polin, R. A. A neonatal sequential organ failure assessment score predicts mortality to late-onset sepsis in preterm very low birth weight infants. Pediatr. Res. 88, 85–90 (2020).
doi: 10.1038/s41390-019-0517-2
pubmed: 31394566
Dorner, R. A., Burton, V. J., Allen, M. C., Robinson, S. & Soares, B. P. Preterm neuroimaging and neurodevelopmental outcome: A focus on intraventricular hemorrhage, post-hemorrhagic hydrocephalus, and associated brain injury. J. Perinatol. 38, 1431–1443 (2018).
doi: 10.1038/s41372-018-0209-5
pubmed: 30166622
pmcid: 6215507
Bakdash, J. Z. & Marusich, L. R. Repeated Measures Correlation. Front. Psychol. 8, (2017). https://doi.org/10.3389/fpsyg.2017.00456 .
Papile, L. A., Burstein, J., Burstein, R. & Koffler, H. Incidence and evolution of subependymal and intraventricular hemorrhage: A study of infants with birth weights less than 1500 gm. J. Pediatr. 92, 529–534 (1978).
doi: 10.1016/S0022-3476(78)80282-0
pubmed: 305471
Morris, I. P., Goel, N. & Chakraborty, M. Efficacy and safety of systemic hydrocortisone for the prevention of bronchopulmonary dysplasia in preterm infants: A systematic review and meta-analysis. Eur. J. Pediatr. 178, 1171–1184 (2019).
doi: 10.1007/s00431-019-03398-5
pubmed: 31144162
pmcid: 6647381
Williams, E. E., Dassios, T., Mann, M. & Greenough, A. The effect of postnatal corticosteroids on growth parameters in infants with bronchopulmonary dysplasia. J. Perinat. Med. 49, 1141–1144 (2021).
doi: 10.1515/jpm-2021-0149
pubmed: 34087969
Spanswick, S. C., Epp, J. R. & Sutherland, R. J. Time-course of hippocampal granule cell degeneration and changes in adult neurogenesis after adrenalectomy in rats. Neuroscience 190, 166–176 (2011).
doi: 10.1016/j.neuroscience.2011.06.023
pubmed: 21704680
Gould, E., Woolley, C. S. & McEwen, B. S. Short-term glucocorticoid manipulations affect neuronal morphology and survival in the adult dentate gyrus. Neuroscience 37, 367–375 (1990).
doi: 10.1016/0306-4522(90)90407-U
pubmed: 2133348
Numakawa, T. et al. Glucocorticoid receptor interaction with TrkB promotes BDNF-triggered PLC-gamma signaling for glutamate release via a glutamate transporter. Proc. Natl Acad. Sci. USA 106, 647–652 (2009).
doi: 10.1073/pnas.0800888106
pubmed: 19126684
pmcid: 2626757
Jeanneteau, F., Garabedian, M. J. & Chao, M. V. Activation of Trk neurotrophin receptors by glucocorticoids provides a neuroprotective effect. Proc. Natl Acad. Sci. USA 105, 4862–4867 (2008).
doi: 10.1073/pnas.0709102105
pubmed: 18347336
pmcid: 2290769
Bellavance, M.-A. & Rivest, S. The neuroendocrine control of the innate immune system in health and brain diseases. Immunol. Rev. 248, 36–55 (2012).
doi: 10.1111/j.1600-065X.2012.01129.x
pubmed: 22725953
Liston, C. & Gan, W.-B. Glucocorticoids are critical regulators of dendritic spine development and plasticity in vivo. Proc. Natl Acad. Sci. 108, 16074–16079 (2011).
doi: 10.1073/pnas.1110444108
pubmed: 21911374
pmcid: 3179117
Liston, C. et al. Circadian glucocorticoid oscillations promote learning-dependent synapse formation and maintenance. Nat. Neurosci. 16, 698–705 (2013).
doi: 10.1038/nn.3387
pubmed: 23624512
pmcid: 3896394
Aucott, S. W., Donohue, P. K. & Northington, F. J. Increased morbidity in severe early intrauterine growth restriction. J. Perinatol. J. Calif. Perinat. Assoc. 24, 435–440 (2004).
Ullian, M. E. The role of corticosteroids in the regulation of vascular tone. Cardiovasc. Res. 41, 55–64 (1999).
doi: 10.1016/S0008-6363(98)00230-2
pubmed: 10325953
Lösel, R. & Wehling, M. Nongenomic actions of steroid hormones. Nat. Rev. Mol. Cell Biol. 4, 46–55 (2003).
doi: 10.1038/nrm1009
pubmed: 12511868
Puia-Dumitrescu, M. et al. Dexamethasone, Prednisolone, and Methylprednisolone Use and 2-Year Neurodevelopmental Outcomes in Extremely Preterm Infants. JAMA Netw. Open 5, e221947 (2022).
doi: 10.1001/jamanetworkopen.2022.1947
pubmed: 35275165
pmcid: 8917427